Cargando…

571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed

BACKGROUND: HIV-infected African-Americans [AA] are more likely to experience virologic failure (VF) compared with other ethnic groups. Decreased access to healthcare has been postulated as a potential cause. Using data from the US Military Natural History Study (NHS), we examined the effects of rac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganesan, Anuradha, Won, Seunghyun, Joya, Christie, Deiss, Robert, Maves, Ryan, Kronmann, Karl, Lalani, Tahaniyat, Schofield, Christina, Whitman, Timothy J, Okulicz, Jason, Agan, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253896/
http://dx.doi.org/10.1093/ofid/ofy210.579
_version_ 1783373599387680768
author Ganesan, Anuradha
Won, Seunghyun
Joya, Christie
Deiss, Robert
Maves, Ryan
Kronmann, Karl
Lalani, Tahaniyat
Schofield, Christina
Whitman, Timothy J
Okulicz, Jason
Agan, Brian
author_facet Ganesan, Anuradha
Won, Seunghyun
Joya, Christie
Deiss, Robert
Maves, Ryan
Kronmann, Karl
Lalani, Tahaniyat
Schofield, Christina
Whitman, Timothy J
Okulicz, Jason
Agan, Brian
author_sort Ganesan, Anuradha
collection PubMed
description BACKGROUND: HIV-infected African-Americans [AA] are more likely to experience virologic failure (VF) compared with other ethnic groups. Decreased access to healthcare has been postulated as a potential cause. Using data from the US Military Natural History Study (NHS), we examined the effects of race on VF. The NHS is a longitudinal cohort comprised of Department of Defense (DoD) beneficiaries with unrestricted access to healthcare. METHODS: We included NHS participants who contributed follow-up after 2001. Demographic characteristics, antiretroviral therapy (ART) history, and serial viral loads (VL) were obtained from the database. Pharmacy records were used to calculate adherence. VF was defined as a VL of (3)200 copies/mL on two consecutive measurements or one VL of >1,000 c/mL. A Cox model with time-updated covariates was used to examine the association between race and VF. RESULTS: A total of 1,521 subjects contributed follow-up after 2001 (41% AA; 95% male). Median age, CD4 count and VL at ART initiation (AI) were 31.6 years [IQR 26–39], 367 cells/μl [IQR 271–489] and 4.6 log(10) copies/mL [IQR 4.0–5.0], respectively. Subjects were followed for a median of 4.8 years [IQR 2.7–7.9], and 13.2% (n = 201) met criteria for VF. Most subjects initiated ART with a non-nucleoside reverse transcriptase inhibitor (NNRTI) (64%), integrase strand transferase inhibitor (InSTI) (15%) or a boosted protease inhibitor (PI) (14%)-based regimen. Results of the adjusted Cox model are in the table below. CONCLUSION: In the NHS, in recent years, AA and Caucasians have similar responses to ART. NNRTI and InsTI use was protective, reinforcing that simpler medications with fewer adverse effects improve outcomes. Unrestricted access to care and modernization of ART should help narrow the disparities observed in virologic outcomes. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253896
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62538962018-11-28 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed Ganesan, Anuradha Won, Seunghyun Joya, Christie Deiss, Robert Maves, Ryan Kronmann, Karl Lalani, Tahaniyat Schofield, Christina Whitman, Timothy J Okulicz, Jason Agan, Brian Open Forum Infect Dis Abstracts BACKGROUND: HIV-infected African-Americans [AA] are more likely to experience virologic failure (VF) compared with other ethnic groups. Decreased access to healthcare has been postulated as a potential cause. Using data from the US Military Natural History Study (NHS), we examined the effects of race on VF. The NHS is a longitudinal cohort comprised of Department of Defense (DoD) beneficiaries with unrestricted access to healthcare. METHODS: We included NHS participants who contributed follow-up after 2001. Demographic characteristics, antiretroviral therapy (ART) history, and serial viral loads (VL) were obtained from the database. Pharmacy records were used to calculate adherence. VF was defined as a VL of (3)200 copies/mL on two consecutive measurements or one VL of >1,000 c/mL. A Cox model with time-updated covariates was used to examine the association between race and VF. RESULTS: A total of 1,521 subjects contributed follow-up after 2001 (41% AA; 95% male). Median age, CD4 count and VL at ART initiation (AI) were 31.6 years [IQR 26–39], 367 cells/μl [IQR 271–489] and 4.6 log(10) copies/mL [IQR 4.0–5.0], respectively. Subjects were followed for a median of 4.8 years [IQR 2.7–7.9], and 13.2% (n = 201) met criteria for VF. Most subjects initiated ART with a non-nucleoside reverse transcriptase inhibitor (NNRTI) (64%), integrase strand transferase inhibitor (InSTI) (15%) or a boosted protease inhibitor (PI) (14%)-based regimen. Results of the adjusted Cox model are in the table below. CONCLUSION: In the NHS, in recent years, AA and Caucasians have similar responses to ART. NNRTI and InsTI use was protective, reinforcing that simpler medications with fewer adverse effects improve outcomes. Unrestricted access to care and modernization of ART should help narrow the disparities observed in virologic outcomes. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253896/ http://dx.doi.org/10.1093/ofid/ofy210.579 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ganesan, Anuradha
Won, Seunghyun
Joya, Christie
Deiss, Robert
Maves, Ryan
Kronmann, Karl
Lalani, Tahaniyat
Schofield, Christina
Whitman, Timothy J
Okulicz, Jason
Agan, Brian
571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
title 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
title_full 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
title_fullStr 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
title_full_unstemmed 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
title_short 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
title_sort 571. in a well-characterized cohort with universal access to care and medications racial disparities in hiv virologic outcomes are no longer observed
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253896/
http://dx.doi.org/10.1093/ofid/ofy210.579
work_keys_str_mv AT ganesananuradha 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT wonseunghyun 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT joyachristie 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT deissrobert 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT mavesryan 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT kronmannkarl 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT lalanitahaniyat 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT schofieldchristina 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT whitmantimothyj 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT okuliczjason 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved
AT aganbrian 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved